Intelligent Bio Solutions Inc. (INBS)

NASDAQ: INBS · IEX Real-Time Price · USD
0.311
-0.020 (-6.01%)
At close: Dec 6, 2022 3:49 PM
0.330
+0.019 (5.97%)
After-hours: Dec 6, 2022 4:00 PM EST
-6.01%
Market Cap 7.05M
Revenue (ttm) 748,466
Net Income (ttm) -8.08M
Shares Out 14.89M
EPS (ttm) -0.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 33,795
Open 0.35
Previous Close 0.331
Day's Range 0.3 - 0.35
52-Week Range 0.272 - 1.98
Beta n/a
Analysts n/a
Price Target 4.59 (+1,374.0%)
Earnings Date n/a

About INBS

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins... [Read more]

Industry Medical Devices
Founded 2016
Employees 12
Stock Exchange NASDAQ
Ticker Symbol INBS
Full Company Profile

Financial Performance

In 2022, INBS's revenue was $437,146, a decrease of -77.93% compared to the previous year's $1.98 million. Losses were -$8.31 million, 18.0% more than in 2021.

Financial Statements

News

Intelligent Bio Solutions Inc. Reports First Quarter Ending September 30, 2022, Preliminary Financial Results and Rec...

- Acquired Intelligent Fingerprinting Limited and its proprietary drugs of abuse screening technology -

3 weeks ago - GlobeNewsWire

Intelligent Bio Solutions Inc. (INBS) Announces UK-Wide Glass Manufacturer to Roll Out Non-Invasive Drug Screening Sy...

- Can now test 1,000 employees across six sites as required, with each test always taking only ten minutes - - Can now test 1,000 employees across six sites as required, with each test always taking onl...

4 weeks ago - GlobeNewsWire

Intelligent Bio Solutions Inc. Announces Airline Adopts Fingerprint Drug Screening System for In-house Testing

- Eastern Airways to use portable, hygienic, non-invasive fingerprint sweat test to support new European Aviation Authority regulations -

1 month ago - GlobeNewsWire

Intelligent Bio Solutions Inc. to Present First Quarter 2023 Financial Results and Recent Corporate Update on November 9

- Company to Host Conference Call & Webcast at 4:30 p.m. ET - - Company to Host Conference Call & Webcast at 4:30 p.m. ET -

1 month ago - GlobeNewsWire

Intelligent Bio Solutions Inc. Announces Leading U.K. Container Haulier Switching to Fingerprint Drug Screening Syste...

Goldstar Transport to Remove Urine Testing for Sweat Based Technology Goldstar Transport to Remove Urine Testing for Sweat Based Technology

1 month ago - GlobeNewsWire

GBS Inc. Initiates Company Name Change to Intelligent Bio Solutions Inc. (IBSS) and Announces Key Executive Appointments

- Name change to more closely reflect firm's expanding portfolio of intelligent, efficient, convenient and practical noninvasive and drug testing technologies and products -

1 month ago - GlobeNewsWire

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) --  GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at ...

2 months ago - GlobeNewsWire

GBS Inc. Reports Fourth Quarter and Full Year ended June 30, 2022 Preliminary Financial Results and Recent Business H...

- Entered into exclusive agreement with Intelligent Fingerprinting Ltd. (IFP) for screening technology focused on drugs of abuse towards a prospective acquisition -

3 months ago - GlobeNewsWire

GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31

Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET

3 months ago - GlobeNewsWire

GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and Blood

NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at p...

4 months ago - GlobeNewsWire

GBS Inc. to Initiate Manufacturing on the University of Newcastle Australia Campus

NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at p...

5 months ago - GlobeNewsWire

GBS INC. Announces Adjournment of 2022 Annual Meeting of Stockholders to July 13, 2022

NEW YORK, June 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at p...

5 months ago - GlobeNewsWire

GBS Inc. Enters into Exclusivity Agreement for an Acquisition of Unique Point of Care Diagnostic Screening Technology...

- Intelligent Fingerprinting Limited's commercial-stage, revenue-generating platform technology would provide an expanded product upon which to leverage the existing GBS pipeline - Intelligent Fingerpri...

5 months ago - GlobeNewsWire

GBS Inc. to Present at the H.C. Wainwright Global Investment Conference

NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at po...

6 months ago - GlobeNewsWire

GBS Inc. to Hold Virtual 2022 Annual Shareholder Meeting on Thursday, June 16, 2022, at 4:00pm ET

NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at po...

6 months ago - GlobeNewsWire

GBS Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights

- Initiated prospective study to collect coincident samples of oral fluid and blood following IRB approval -

6 months ago - GlobeNewsWire

GBS Inc. to Present Third Quarter 2022 Financial Results and Recent Corporate Update on May 10

Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET

7 months ago - GlobeNewsWire

GBS Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial at Sutter Health Mills-Peninsula Me...

The trial is single center, prospective study to collect coincident samples of oral fluid and blood to evaluate the time-course of glucose

8 months ago - GlobeNewsWire

GBS Inc. to Participate in the Upcoming March Investor Conferences

NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point...

8 months ago - GlobeNewsWire

GBS Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights

- Discussions underway between the University of Newcastle and GBS to oversee the high-tech manufacturing facility supported by its $4.7 Million Grant Funding Award from Australian Government -

9 months ago - GlobeNewsWire

GBS Inc. to Present Second Quarter 2022 Financial Results and Recent Corporate Update on February 10

Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET

9 months ago - GlobeNewsWire

GBS Inc. to Participate in the Upcoming January Virtual Investor Conferences

NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-...

11 months ago - GlobeNewsWire

GBS Inc. Announces Application for FDA Breakthrough Device Designation to Fast Track Rapid Saliva Glucose Test

NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at p...

11 months ago - GlobeNewsWire

GBS Stock: The Covid Antibody Test News Shooting GBS Shares Higher Today

Shares of GBS stock are trading higher after a clinical study at Harvard University yielded positive results for the company's antibody test. The post GBS Stock: The Covid Antibody Test News Shooting GB...

1 year ago - InvestorPlace

GBS Shares Are Rallying On Plans For COVID-19 Antibody Trials After Validation Study

GBS Inc (NASDAQ:GBS) will prepare for clinical trials of its rapid SARS-CoV-2 (COVID-19) Antibody test following the recent successful completion of a clinical validation study. As previously referenced...

1 year ago - Benzinga